
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5984195/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	2.1	1,185
2	Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology, 2015, 45, 161-176.	2.3	1,002
3	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	2.1	693
4	The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurology, The, 2005, 4, 712-717.	10.2	354
5	The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet, The, 2004, 364, 1773-1778.	13.7	320
6	Childhood arterial ischaemic stroke incidence, presenting features, and risk factors: a prospective population-based study. Lancet Neurology, The, 2014, 13, 35-43.	10.2	291
7	Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychological Medicine, 2003, 33, 335-344.	4.5	261
8	The Influence of Head Growth in Fetal Life, Infancy, and Childhood on Intelligence at the Ages of 4 and 8 Years. Pediatrics, 2006, 118, 1486-1492.	2.1	252
9	Critical periods of brain growth and cognitive function in children. Brain, 2004, 127, 321-329.	7.6	247
10	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	2.1	230
11	The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: Evidence from the United Kingdom Infantile Spasms Study. Epilepsia, 2011, 52, 1359-1364.	5.1	215
12	Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet, The, 1998, 351, 1490.	13.7	210
13	Ophthalmic manifestations of tuberous sclerosis: a population based study. British Journal of Ophthalmology, 2001, 85, 420-423.	3.9	203
14	Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurology, The, 2017, 16, 33-42.	10.2	199
15	The underlying etiology of infantile spasms (West syndrome): Information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification ² . Epilepsia, 2010, 51, 2168-2174.	5.1	194
16	The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Archives of Disease in Childhood, 2004, 89, 530-533.	1.9	189
17	Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurology, The, 2011, 10, 54-62.	10.2	179
18	An epidemiological study of renal pathology in tuberous sclerosis complex. BJU International, 2004, 94. 853-857.	2.5	168

#	Article	IF	CITATIONS
19	CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. Journal of Medical Genetics, 2006, 43, 729-734.	3.2	167
20	TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients. Orphanet Journal of Rare Diseases, 2017, 12, 2.	2.7	166
21	Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. European Journal of Paediatric Neurology, 2018, 22, 738-748.	1.6	151
22	Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. JAMA Neurology, 2021, 78, 285.	9.0	139
23	Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Archives of Disease in Childhood, 2010, 95, 382-386.	1.9	138
24	Epilepsy in tuberous sclerosis complex: Findings from the <scp>TOSCA</scp> Study. Epilepsia Open, 2019, 4, 73-84.	2.4	125
25	Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. The Lancet Child and Adolescent Health, 2018, 2, 715-725.	5.6	114
26	TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet Journal of Rare Diseases, 2018, 13, 157.	2.7	106
27	Oily fish intake during pregnancy – association with lower hyperactivity but not with higher fullâ€scale IQ in offspring. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2008, 49, 1061-1068.	5.2	96
28	Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy. Brain, 2010, 133, 2964-2970.	7.6	95
29	Diagnostic delays in paediatric stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 917-921.	1.9	92
30	Causes of mortality in individuals with tuberous sclerosis complex. Developmental Medicine and Child Neurology, 2017, 59, 612-617.	2.1	87
31	Use of melatonin to treat sleep disorders in tuberous sclerosis. Developmental Medicine and Child Neurology, 1999, 41, 123-126.	2.1	77
32	The epidemiology of childhood stroke. European Journal of Paediatric Neurology, 2010, 14, 197-205.	1.6	75
33	The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. British Journal of Clinical Pharmacology, 2019, 85, 37-46.	2.4	70
34	Tuberous sclerosis complex and Wolff-Parkinson-White syndrome. Archives of Disease in Childhood, 1998, 78, 159-162.	1.9	63
35	TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet Journal of Rare Diseases, 2014, 9, 182.	2.7	62
36	Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrology Dialysis Transplantation, 2019, 34, 502-508.	0.7	55

#	Article	IF	CITATIONS
37	Treatment of primary angiitis of the central nervous system in childhood with mycophenolate mofetil. Rheumatology, 2010, 49, 806-811.	1.9	54
38	Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ, The, 2020, 368, m331.	6.0	53
39	Outcome and recurrence 1 year after pediatric arterial ischemic stroke in a populationâ€based cohort. Annals of Neurology, 2016, 79, 784-793.	5.3	51
40	The Relative Effect of Size at Birth, Postnatal Growth and Social Factors on Cognitive Function in Late Childhood. Annals of Epidemiology, 2006, 16, 469-476.	1.9	48
41	Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study. Archives of Disease in Childhood, 2008, 93, 751-754.	1.9	48
42	The underlying etiology of infantile spasms (West syndrome): Information from the International Collaborative Infantile Spasms Study (<scp>ICISS</scp>). Epilepsia, 2019, 60, 1861-1869.	5.1	48
43	Diagnosis of tuberous sclerosis complex in the fetus. European Journal of Paediatric Neurology, 2018, 22, 1027-1034.	1.6	46
44	Effect of Melatonin Dosage on Sleep Disorder in Tuberous Sclerosis Complex. Journal of Child Neurology, 2005, 20, 78-80.	1.4	40
45	Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis. Journal of Intellectual Disability Research, 2006, 50, 561-569.	2.0	39
46	Cerebral venous sinus thrombosis: a case series including thrombolysis. Archives of Disease in Childhood, 2009, 94, 790-794.	1.9	38
47	Epileptic spasms — 175 years on: Trying to teach an old dog new tricks. Seizure: the Journal of the British Epilepsy Association, 2017, 44, 81-86.	2.0	38
48	Non-penetrance in tuberous sclerosis. Lancet, The, 2000, 355, 1698.	13.7	36
49	An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms. Developmental Medicine and Child Neurology, 2013, 55, 862-867.	2.1	36
50	Recent advances: Advances in the understanding of tuberous sclerosis. Archives of Disease in Childhood, 2000, 83, 140-142.	1.9	35
51	Longâ€ŧerm cognitive outcomes in tuberous sclerosis complex. Developmental Medicine and Child Neurology, 2020, 62, 322-329.	2.1	35
52	The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. European Journal of Paediatric Neurology, 2013, 17, 36-44.	1.6	33
53	Mortality from childhood stroke in England and Wales, 1921-2000. Archives of Disease in Childhood, 2010, 95, 12-19.	1.9	32
54	Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. Frontiers in Neurology, 2020, 11, 972.	2.4	27

#	Article	IF	CITATIONS
55	The UK guidelines for management and surveillance of Tuberous Sclerosis Complex. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 171-182.	0.5	26
56	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. Frontiers in Neurology, 2019, 10, 705.	2.4	22
57	Research governance delays for a multicentre non-interventional study. Journal of the Royal Society of Medicine, 2009, 102, 195-198.	2.0	21
58	Planning interventional trials in childhood arterial ischaemic stroke using a Delphi consensus process. Developmental Medicine and Child Neurology, 2017, 59, 713-718.	2.1	21
59	Trends in Epilepsy Mortality in England and Wales and the United States, 1950-1994. American Journal of Epidemiology, 2000, 151, 182-189.	3.4	20
60	Quality of life in patients with Tuberous Sclerosis Complex (TSC). European Journal of Paediatric Neurology, 2019, 23, 801-807.	1.6	20
61	Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study. Frontiers in Neurology, 2020, 11, 904.	2.4	20
62	Tuberous sclerosiswhat's new?. Archives of Disease in Childhood, 2008, 93, 728-731.	1.9	19
63	Risk factors and treatment outcomes of childhood stroke. Expert Review of Neurotherapeutics, 2010, 10, 1331-1346.	2.8	19
64	Duration of Breast Feeding and Cognitive Function: Population Based Cohort Study. European Journal of Epidemiology, 2006, 21, 435-441.	5.7	18
65	Juvenile parkinsonism associated with heterozygous frameshift ATP13A2 gene mutation. European Journal of Paediatric Neurology, 2011, 15, 271-275.	1.6	18
66	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. Frontiers in Neurology, 2019, 10, 821.	2.4	18
67	Melatonin Excretion in Normal Children and in Tuberous Sclerosis Complex With Sleep Disorder Responsive to Melatonin. Journal of Child Neurology, 2005, 20, 21-25.	1.4	17
68	Renal angiomyolipomata and learning difficulty in tuberous sclerosis complex. Journal of Medical Genetics, 2000, 37, 156-157.	3.2	16
69	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. Journal of Neurodevelopmental Disorders, 2020, 12, 24.	3.1	16
70	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA). Orphanet Journal of Rare Diseases, 2021, 16, 301.	2.7	15
71	The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial. EClinicalMedicine, 2021, 32, 100715.	7.1	13
72	Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry. Frontiers in Neurology, 2021, 12, 697467.	2.4	13

#	Article	IF	CITATIONS
73	Outcomes following childhood arterial ischaemic stroke: A Delphi Consensus on what parents want from future research. European Journal of Paediatric Neurology, 2015, 19, 181-187.	1.6	11
74	Immunotherapy for arterial ischaemic stroke in childhood: a systematic review. Archives of Disease in Childhood, 2017, 102, 410-415.	1.9	11
75	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. Frontiers in Neurology, 2019, 10, 1144.	2.4	11
76	Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care. Frontiers in Neurology, 2019, 10, 1116.	2.4	11
77	Secular changes in severity of intellectual disability in tuberous sclerosis complex: A reflection of improved identification and treatment of epileptic spasms?. Epilepsia Open, 2018, 3, 276-280.	2.4	10
78	TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. Frontiers in Neurology, 2021, 12, 630378.	2.4	10
79	Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype. Frontiers in Neurology, 2020, 11, 603.	2.4	7
80	Epilepsy related mortality. Archives of Disease in Childhood, 2004, 89, 705-707.	1.9	6
81	A machine learning approach to identify cases of cerebral palsy using the UK primary care database. Lancet, The, 2018, 392, S33.	13.7	6
82	Childhood haemorrhagic stroke: a 7-year single-centre experience. Archives of Disease in Childhood, 2019, 104, 1198-1202.	1.9	6
83	Infantile spasms and vigabatrin. BMJ: British Medical Journal, 1999, 318, 56-56.	2.3	6
84	External hydrocephalus and subdural bleeding in infancy associated with transplacental anti-Ro antibodies. Archives of Disease in Childhood, 2012, 97, 316-319.	1.9	5
85	Diagnostic algorithm for children presenting with epilepsia partialis continua. Epilepsia, 2020, 61, 2224-2233.	5.1	5
86	Prevalence of tuberous sclerosis in UK. Lancet, The, 1998, 352, 319.	13.7	3
87	Running an international paediatric non-commercial clinical trial. Archives of Disease in Childhood, 2009, 94, 729-733.	1.9	3
88	Glossal hamartoma in tuberous sclerosis. Archives of Disease in Childhood, 2013, 98, 161-161.	1.9	3
89	Prospective studies of the incidence of pediatric arterial ischaemic stroke. Blood Cells, Molecules, and Diseases, 2018, 69, 101.	1.4	3
90	The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases. Frontiers in Neurology, 2019, 10, 1182.	2.4	3

#	Article	IF	CITATIONS
91	Epilepsy and cannabis: so near, yet so far. Developmental Medicine and Child Neurology, 2022, 64, 162-167.	2.1	3
92	Autismwhat is it and where does it come from?. QJM - Monthly Journal of the Association of Physicians, 2002, 95, 263-265.	0.5	2
93	Shaken impact syndrome. Lancet, The, 2001, 357, 1207.	13.7	1
94	Status epilepticus: Beyond guidelines. Current Paediatrics, 2005, 15, 324-332.	0.2	1
95	Prophylactic Antiepileptic Treatment in Tuberous Sclerosis. Pediatric Neurology, 2020, 110, 100-101.	2.1	1
96	The management of tuberous sclerosis. Current Paediatrics, 2003, 13, 365-370.	0.2	0
97	Epilepsy in childhood and quality of life. European Journal of Paediatric Neurology, 2015, 19, 276-277.	1.6	0
98	CAUSES OF MORTALITY IN INDIVIDUALS WITH TUBEROUS SCLEROSIS COMPLEX (TSC). Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.207-e1.	1.9	0
99	Musculoskeletal involvement in tuberous sclerosis. Archives of Disease in Childhood, 2017, 102, 178-178.	1.9	0
100	The essential symbiosis of academic and clinical neurology. Developmental Medicine and Child Neurology, 2018, 60, 5-5.	2.1	0
101	Cannabis derived medicinal products in child neurology. Developmental Medicine and Child Neurology, 2019, 61, 622-622.	2.1	0
102	Foreword. Developmental Medicine and Child Neurology, 2021, 63, 3-3.	2.1	0